RICHMOND, VA and LONDON, UK September 7, 2012 AmpliPhi Biosciences Corporation (APHB.PK), the leader in the development of bacteriophage-based anti-bacterial therapies to treat resistant bacterial infections, will present at this year’s Rodman & Renshaw Annual Global Investment Conference in New York.
The presentation will be given by CEO, Philip J. Young on Monday, September 10, 2012 at 4:05PM US Eastern Time, and will provide an update to the market on progress that Ampliphi has made in the last twelve months since its creation in 2011 through the merger of Biocontrol Ltd with Targeted Genetics Inc.
AmpliPhi BioSciences Corporation [APHB.PK], created in 2011 through the merger of Biocontrol Limited with Targeted Genetics Inc., is a biotechnology company dedicated to the development of innovative antibacterial solutions to improve human health through the application of its proprietary bacteriophage platform. The Company’s lead product development programs are targeting Gram-negative infections that are often resistant to existing antibiotic treatments. For more information, please visit www.ampliphibio.com
For further information please contact:
At the Company:
Phil Young, CEO